Pharma

Giroctocogene fitelparvovec, a novel gene therapy, demonstrated superiority to routine therapy in treating hemophilia A. Giroctocogene fitelparvovec resulted in a...

A dose-dependent slowing in Huntington's disease progression was observed after 24 months in patients receiving high-dose AMT-130. The gene therapy...

Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median...

83% of participants on an oral Sirturo-containing regimen achieved a favorable outcome compared to 71% of patients on the control...

1. Approximately 88% of patients with GD2-positive diffuse midline glioma or other progressive CNS tumours receiving C7R-GD2.CARTs had a partial...

Patients on pemvidutide experienced only 21.9% of weight loss attributable to lean mass. Pemvidutide preserves muscle tissue and prioritizes fat...

Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution...

The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination...

ETH47, a nasally administered mRNA drug candidate was safe,well-tolerated by healthy participants, and did not result in any clinically relevant...

Patients with familial chylomicronemia syndrome (FCS) treated with plozasiran demonstrated a maximum reduction of 98% in triglyceride levels at month...